Vascular Access Nursing Statistics in 2026

Table of contents

• At a glance
• Vascular access nursing statistics by access type
• Complication and infection benchmarks
• What the 2024 evidence says about ultrasound guidance
• Risk factors that change outcomes
• How nurses can use these numbers in practice

At a glance

Vascular access nursing is a high-volume, high-stakes part of care because the numbers are large and the failure points are predictable. The supplied evidence points to a simple pattern: more patients need access than many teams expect, longer dwell times raise risk, and ultrasound guidance can improve success in difficult access scenarios (WHO 2024 guidance; CDC catheter infection prevention guidance; PubMed 36507736).

Fast facts

• Up to 70% of inpatients may need a peripheral vein or artery catheter during hospitalization (WHO 2024 guidance).
• The WHO 2024 peripheral-catheter guidance includes 14 good practice statements and 23 recommendations for health workers (WHO 2024 guidance).
• The 2024 PIVC meta-analysis pooled 478,586 peripheral intravenous catheters and concluded that more than 2 billion peripheral intravenous catheters are used globally each year (PubMed 38142634).
• The same review found all-cause PIVC failure in 36.4% of catheters before treatment completion (PubMed 38142634).
• CDC guidance says adult peripheral catheters do not need routine replacement more often than every 72 to 96 hours (CDC catheter infection prevention guidance).
• Ultrasound guidance improved difficult-access outcomes, including RR 1.50 for first-pass success and RR 1.40 for overall cannulation success in the 2022 Cochrane review (PubMed 36507736).

Big picture: the dataset shows vascular access nursing is not just about placement. It is about preventing failure, limiting complications, and choosing the right device strategy for the expected dwell time and patient risk.

Vascular access nursing statistics by access type

The clearest way to read the data is by access type, because each device category carries a different failure profile, dwell-time pattern, and complication burden.

Peripheral intravenous catheters

Peripheral intravenous catheters dominate day-to-day nursing workflows, but they are also the most failure-prone access type in the dataset. The 2024 PIVC infection and failure meta-analysis included 41 observational studies and 28 randomized controlled trials, covering 478,586 peripheral intravenous catheters and 78,891 catheter-days of failure data (PubMed 38142634).

That review found:

• 0.028% catheter-associated bloodstream infection among PIVCs (PubMed 38142634).
• 4.40 catheter-associated bloodstream infections per 100,000 catheter-days (PubMed 38142634).
• 0.150% local infection among PIVCs (PubMed 38142634).
• 65.1 local infections per 100,000 catheter-days (PubMed 38142634).
• 36.4% all-cause PIVC failure before treatment completion (PubMed 38142634).
• 4.42 failures per 100 catheter-days (PubMed 38142634).

The practical message for nursing is straightforward: a catheter can be clinically acceptable and still fail early because infiltration, occlusion, dislodgement, phlebitis, or infection disrupts therapy before the treatment course ends.

Midline catheters

Midline catheters often sit between short peripheral access and central access in terms of dwell time and maintenance burden. The midline systematic review included 18,972 midline catheters across five countries and screened 987 articles before analyzing 31 manuscripts (PubMed 33372744).

The review reported:

• Average dwell time of 16.3 days in 4,412 catheters (PubMed 33372744).
• Adjusted mean infection rate of 0.28 per 1,000 catheter-days (PubMed 33372744).
• 64% of studies reported no midline catheter infections (PubMed 33372744).
• Midline failure rate of 12.5% (PubMed 33372744).
• Deep vein thrombosis at 4.1% (PubMed 33372744).
• Dislodgement at 5.0% (PubMed 33372744).
• Occlusion at 3.8% (PubMed 33372744).
• Phlebitis at 3.4% (PubMed 33372744).
• Infiltration at 1.9% (PubMed 33372744).

The midline numbers are useful because they show why a longer dwell time does not automatically mean a lower workload. The device may be more durable than a short peripheral line, but the maintenance needs remain significant enough that failure still shows up across several mechanisms.

Central venous catheters

Central venous catheters carry a different risk profile: fewer placements than peripheral lines, but higher-stakes complications when they go wrong. The 2024 CVC meta-analysis summary cited about 3% major complications associated with placements and reported 20.4 placement failures per 1,000 catheters placed (PubMed 38436976; CDC 2024 CVC meta-analysis summary).

Other estimates from the same meta-analysis were:

• 2.8 arterial cannulations per 1,000 catheters placed (PubMed 38436976).
• 16.2 arterial punctures per 1,000 catheters placed (PubMed 38436976).
• 4.4 pneumothoraces per 1,000 catheters placed (PubMed 38436976).
• 5.5 malfunctions per 1,000 catheter-days (PubMed 38436976).
• 4.8 infections per 1,000 catheter-days (PubMed 38436976).
• 2.7 DVTs per 1,000 catheter-days (PubMed 38436976).
• 30.2 in 1,000 patients with a CVC for 3 days would develop at least one serious complication (PubMed 38436976).

Complication and infection benchmarks

A useful way to think about vascular access nursing statistics is as a chain of failure points. Some numbers describe insertion problems, others describe maintenance complications, and others describe the downstream cost of choosing the wrong device for the expected duration.

Comparison table

Device or issue	Key statistic	Source label
Inpatient need for peripheral vein or artery catheter	Up to 70% of inpatients	WHO 2024 guidance
Peripheral catheter guidance statements	14 good practice statements and 23 recommendations	WHO 2024 guidance
PIVC all-cause failure	36.4% before treatment completion	PubMed 38142634
Midline failure	12.5%	PubMed 33372744
Midline average dwell time	16.3 days	PubMed 33372744
CVC placement failure	20.4 per 1,000 catheters placed	PubMed 38436976
CVC major complications	About 3%	CDC 2024 CVC meta-analysis summary
CVC serious complication risk over 3 days	30.2 per 1,000 patients	PubMed 38436976
Adult peripheral catheter replacement interval	72 to 96 hours	CDC catheter infection prevention guidance

This table shows the essential nursing tradeoff: short-term peripheral lines are common but failure-prone, midlines reduce some short-horizon churn but still fail often enough to matter, and CVCs concentrate complexity into fewer but more serious adverse events.

Infection burden in context

The infection-related figures are notable because they are not interchangeable. The 2024 PIVC review found catheter-associated bloodstream infection in only 0.028% of PIVCs, but because the denominator is so large, the absolute burden still matters (PubMed 38142634).

The midline review showed an adjusted mean infection rate of 0.28 per 1,000 catheter-days and found that 64% of studies reported no midline catheter infections (PubMed 33372744).

For CVCs, the meta-analysis estimated 4.8 infections per 1,000 catheter-days (PubMed 38436976).

Those numbers are not directly interchangeable because the devices, populations, dwell times, and placement contexts differ. Even so, the direction is clear: infection risk is low in proportion terms for some devices, but the clinical consequences and aggregate burden remain large because vascular access is so common.

Cost and prevention thresholds

CDC guidance adds a prevention-and-cost lens that is highly practical for teams responsible for supply choices. It says chlorhexidine/silver sulfadiazine or minocycline/rifampin impregnated CVCs are appropriate when catheters are expected to remain in place for more than 5 days and CLABSI rates are not decreasing (CDC catheter infection prevention guidance).

The same guidance notes:

• >$0.5% chlorhexidine preparation with alcohol is part of the bundled insertion strategy for CLABSI prevention (CDC catheter infection prevention guidance).
• Chlorhexidine/silver sulfadiazine catheters can save $68 to $391 per catheter in high-risk settings (CDC catheter infection prevention guidance).
• Those impregnated catheters may be cost effective when infection rates exceed 3.3 per 1,000 catheter-days (CDC catheter infection prevention guidance).
• Second-generation chlorhexidine/silver sulfadiazine catheters have three times the amount of chlorhexidine on the external surface compared with first-generation catheters (CDC catheter infection prevention guidance).

What the 2024 evidence says about ultrasound guidance

Ultrasound guidance is one of the clearest evidence-backed interventions in the dataset because it affects access success rather than only downstream complications.

Peripheral and difficult-access patients

The 2022 Cochrane review in difficult-access adults found that ultrasound guidance increased:

• First-pass success with RR 1.50 (PubMed 36507736).
• Overall cannulation success with RR 1.40 (PubMed 36507736).

A separate study found ultrasound-guided peripheral IV cannulation was associated with a two-times higher likelihood of first successful cannulation with OR 2.1 (PubMed 34353670).

That aligns with the operating-room pediatric trial, where ultrasound reduced:

• First-attempt failure to RR 0.23 (PubMed 23415740).
• Number of attempts by 1.50 on average (PubMed 23415740).
• Procedure time by 5.95 minutes on average (PubMed 23415740).

Why success metrics matter to nurses

Placement success is not a vanity metric. It affects patient comfort, therapy delays, staff workload, and the probability of needing repeated attempts. Repeated attempts can push a case from routine into difficult access, and difficult access often cascades into slower medication delivery and more device replacements.

The ultrasound numbers matter even more when you consider how often access is needed in the first place. If up to 70% of inpatients need a peripheral vein or artery catheter (WHO 2024 guidance), then even a modest improvement in first-pass success can scale across a very large patient base.

A practical reading of the evidence

The best inference from the supplied numbers is that ultrasound should be treated as a risk-reduction and efficiency tool, especially for difficult access. The evidence does not say every patient needs ultrasound. It does say the benefit is large enough in hard-access settings that it should be part of a serious vascular access strategy.

Risk factors that change outcomes

Nursing practice is not only about the device. It is also about insertion site, dwell time, staff experience, and patient condition.

Peripheral IV risk factors

The 2014 PIVC risk-factor analysis included 3,283 adult patients contributing 5,907 catheters (PubMed 24334800). The risk patterns it reported are clinically useful because they separate insertion location from patient factors and staff factors.

Key findings:

• Hand insertion increased occlusion risk with HR 1.47 versus forearm insertion (PubMed 24334800).
• Antecubital fossa insertion increased occlusion risk with HR 1.27 versus forearm insertion (PubMed 24334800).
• Upper-arm insertion increased occlusion risk with HR 1.25 versus forearm insertion (PubMed 24334800).
• Larger diameter PIVCs increased phlebitis risk with HR 1.48 (PubMed 24334800).
• Operating and radiology suite staff insertions had lower occlusion risk with HR 0.80 versus ward insertion (PubMed 24334800).
• Hand insertion raised accidental-removal risk with HR 2.45 versus forearm insertion (PubMed 24334800).
• Antecubital fossa insertion raised accidental-removal risk with HR 1.65 versus forearm insertion (PubMed 24334800).
• Clinical staff insertion raised accidental-removal risk with HR 1.69 versus intravenous-service insertion (PubMed 24334800).
• Smaller PIVC diameter raised accidental-removal risk with HR 1.29 (PubMed 24334800).
• Female sex raised phlebitis risk with HR 1.64 and occlusion risk with HR 1.44 (PubMed 24334800).

ICU CVC risk factors

The ICU CLABSI meta-analysis screened 654 studies and included 23, with 17 studies in the pooled model (PubMed 38652718). The pooled factors that increased CLABSI odds were:

• Catheterization for at least 5 days: OR 2.07 (PubMed 38652718).
• Catheterization for at least 7 days: OR 3.62 (PubMed 38652718).
• Catheterization for at least 14 days: OR 4.85 (PubMed 38652718).
• Total parenteral nutrition: OR 2.27 (PubMed 38652718).
• Multiple-lumen catheters: OR 3.41 (PubMed 38652718).
• Times of tube indwelling: OR 3.50 (PubMed 38652718).
• Length of ICU stay: OR 4.05 (PubMed 38652718).
• Position of indwelling: OR 2.41 (PubMed 38652718).
• APACHE II score: OR 1.84 (PubMed 38652718).
• Age 60 years or older: OR 2.19 (PubMed 38652718).
• Extensive antibiotic use: OR 3.54 (PubMed 38652718).
• Diabetes mellitus: OR 3.06 (PubMed 38652718).
• Immunosuppression: OR 2.87 (PubMed 38652718).

The strongest pattern here is dwell time. Once catheterization reaches 5, 7, or 14 days, risk rises in a way that is too large for routine care to ignore.

What this means for line selection

The data points toward a few practical selection principles:

• Match device choice to expected therapy duration.
• Avoid assuming the shortest line is always the safest choice.
• Treat ultrasound as a serious option in difficult access cases.
• Pay attention to the insertion site because the site itself changes occlusion and accidental-removal risk.
• Reassess lines before dwell time becomes the main risk driver.

How nurses can use these numbers in practice

The value of vascular access nursing statistics is not academic completeness. It is decision support.

A short decision framework

Use the numbers in this dataset to answer four questions quickly:

1. How many patients will likely need access?

   • Up to 70% of inpatients may need a peripheral vein or artery catheter (WHO 2024 guidance).

2. How long is the device likely to stay in?

   • Adult peripheral catheters do not need routine replacement more often than every 72 to 96 hours (CDC catheter infection prevention guidance).
   • Midlines averaged 16.3 days in the review dataset (PubMed 33372744).
   • CVC risk rises sharply once indwelling duration reaches 5, 7, or 14 days (PubMed 38652718).

3. How hard is the access likely to be?

   • Ultrasound improves first-pass success and overall success in difficult-access adults (PubMed 36507736).
   • It also reduced attempts and procedure time in the pediatric operating-room trial (PubMed 23415740).

4. What complication is most likely to matter?

   • For PIVCs, failure is common at 36.4% (PubMed 38142634).
   • For midlines, failure remains meaningful at 12.5% (PubMed 33372744).
   • For CVCs, major complications and serious events carry the most weight, with about 3% major complications and 30.2 per 1,000 patients experiencing at least one serious complication over 3 days (CDC 2024 CVC meta-analysis summary; PubMed 38436976).

Fast operational takeaways

• Expect high demand for access.
• Plan for failure, not perfection.
• Use ultrasound early when access is difficult.
• Treat dwell time as a risk factor, not just a scheduling detail.
• Choose the device that matches therapy duration and complication tolerance.

Key numbers to remember

• 70% of inpatients may need peripheral access (WHO 2024 guidance).
• 36.4% of PIVCs fail before treatment completion (PubMed 38142634).
• 12.5% of midlines fail in the review data (PubMed 33372744).
• 20.4 per 1,000 CVC placements fail at insertion (PubMed 38436976).
• 1.50 RR first-pass success gain with ultrasound in difficult-access adults (PubMed 36507736).
• 4.85 OR for CLABSI when catheterization reaches 14 days in the ICU meta-analysis (PubMed 38652718).